1284 related articles for article (PubMed ID: 12820452)
21. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
[TBL] [Abstract][Full Text] [Related]
22. Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma.
Mukozu T; Nagai H; Matsui D; Kanekawa T; Sumino Y
Anticancer Res; 2013 Mar; 33(3):1013-21. PubMed ID: 23482775
[TBL] [Abstract][Full Text] [Related]
23. [Detection and evaluation of serum GP73, a resident Golgi glycoprotein, as a marker in diagnosis of hepatocellular carcinoma].
Zhao XY; Li N; Ding HG; Jiang FF
Zhonghua Zhong Liu Za Zhi; 2010 Dec; 32(12):943-5. PubMed ID: 21223806
[TBL] [Abstract][Full Text] [Related]
24. Feasibility of α-fetoprotein as a diagnostic tool for hepatocellular carcinoma in Korea.
Ahn DG; Kim HJ; Kang H; Lee HW; Bae SH; Lee JH; Paik YH; Lee JS
Korean J Intern Med; 2016 Jan; 31(1):46-53. PubMed ID: 26767857
[TBL] [Abstract][Full Text] [Related]
25. Validity of alpha fetoprotein for diagnosis of hepatocellular carcinoma in cirrhosis.
Sarwar S; Khan AA; Tarique S
J Coll Physicians Surg Pak; 2014 Jan; 24(1):18-22. PubMed ID: 24411536
[TBL] [Abstract][Full Text] [Related]
26. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.
Marrero JA; Su GL; Wei W; Emick D; Conjeevaram HS; Fontana RJ; Lok AS
Hepatology; 2003 May; 37(5):1114-21. PubMed ID: 12717392
[TBL] [Abstract][Full Text] [Related]
27. Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis.
Henry L; Lavabre-Bertrand T; Vercambre L; Ramos J; Carillo S; Guiraud I; Pouderoux P; Bismuth M; Valats JC; Demattei C; Duny Y; Chaze I; Funakoshi N; Bureau JP; Daurès JP; Blanc P
Gut; 2009 Jun; 58(6):833-8. PubMed ID: 19201777
[TBL] [Abstract][Full Text] [Related]
28. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases.
Lamerz R; Runge M; Stieber P; Meissner E
Anticancer Res; 1999; 19(4A):2489-93. PubMed ID: 10470180
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis.
Wang Y; Liu YH; Mai SJ; He LJ; Liao YJ; Deng HX; Guan XY; Zeng YX; Kung HF; Xie D
J Gastroenterol Hepatol; 2010 Jun; 25(6):1123-8. PubMed ID: 20594228
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
31. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma.
Kim J; Ki SS; Lee SD; Han CJ; Kim YC; Park SH; Cho SY; Hong YJ; Park HY; Lee M; Jung HH; Lee KH; Jeong SH
Am J Gastroenterol; 2006 Sep; 101(9):2051-9. PubMed ID: 16848813
[TBL] [Abstract][Full Text] [Related]
32. Clinical application of determining serum AFP-IgM complexes for diagnosis of small hepatocellular carcinoma.
Jiang J; Wu C; Shen Y; Xu B; Zheng X; Li X; Xu N
Anticancer Res; 2011 Feb; 31(2):687-91. PubMed ID: 21378357
[TBL] [Abstract][Full Text] [Related]
33. Elevation of serum type IV collagen in liver cancer as well as liver cirrhosis.
Hong WS; Hong SI; Park SY; Son Y; Lee YS; Chung YH; Yang SK; Suh DJ; Min YI
Anticancer Res; 1995; 15(6B):2777-80. PubMed ID: 8669863
[TBL] [Abstract][Full Text] [Related]
34. Differential tumor markers and hepatitis markers profile in liver tumors.
Khalifa A; Mady EA; Abadeer N; Kamal A
Anticancer Res; 1999; 19(4A):2495-500. PubMed ID: 10470181
[TBL] [Abstract][Full Text] [Related]
35. [Two patients with liver cirrhosis who presented with alpha-fetoprotein values diagnostic of hepatocarcinoma but without evidence of neoplasms].
Cristani A; Borghi A; Cioni G; Vignoli A; Ventura E
Recenti Prog Med; 1992 May; 83(5):286-7. PubMed ID: 1279760
[TBL] [Abstract][Full Text] [Related]
36. Highly sensitive lens culinaris agglutinin-reactive α-fetoprotein is useful for early detection of hepatocellular carcinoma in patients with chronic liver disease.
Oda K; Ido A; Tamai T; Matsushita M; Kumagai K; Mawatari S; Saishoji A; Kure T; Ohno K; Toyokura E; Imanaka D; Moriuchi A; Uto H; Oketani M; Hashiguchi T; Tsubouchi H
Oncol Rep; 2011 Nov; 26(5):1227-33. PubMed ID: 21874252
[TBL] [Abstract][Full Text] [Related]
37. Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein <20 ng/mL.
Toyoda H; Kumada T; Tada T; Kaneoka Y; Maeda A; Kanke F; Satomura S
Cancer Sci; 2011 May; 102(5):1025-31. PubMed ID: 21244578
[TBL] [Abstract][Full Text] [Related]
38. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis.
Sterling RK; Jeffers L; Gordon F; Sherman M; Venook AP; Reddy KR; Satomura S; Schwartz ME
Am J Gastroenterol; 2007 Oct; 102(10):2196-205. PubMed ID: 17617202
[TBL] [Abstract][Full Text] [Related]
39. Clinical characteristics among patients with hepatocellular carcinoma according to the serum levels of alpha-fetoprotein and des-y-carboxy prothrombin.
Dohmen K; Shigematsu H; Irie K; Ishibashi H
Hepatogastroenterology; 2003; 50(54):2072-8. PubMed ID: 14696467
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP.
Baek YH; Lee JH; Jang JS; Lee SW; Han JY; Jeong JS; Choi JC; Kim HY; Han SY
Hepatogastroenterology; 2009; 56(91-92):763-7. PubMed ID: 19621698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
